New Once Weekly Investigational Oral Regimen Shows Strong 48 Week Results, Highlighting the Need for Easier HIV Treatment Options
January 16, 2026
Chapel Hill, N.C. — A Phase 2 study led by Dr. Joe Eron, a member of the UNC Institute for Global Health and Infectious Diseases, shows an investigational once‑weekly, all‑oral combination of islatravir (ISL) and lenacapavir(LEN) maintains high levels of virologic suppression through 48 weeks in adults living with HIV....
